Hormonal
SGLT2 inhibitors reduce cardiovascular risk through mechanisms including osmotic diuresis, blood pressure reduction, weight loss, and reduced arterial stiffness, independent of glucose lowering.
SGLT2 inhibitors like empagliflozin help the heart by lowering blood pressure, reducing body weight (specifically fat mass), and making arteries more flexible. These physical changes reduce the workload on the heart and lower the risk of heart failure and cardiovascular death, offering benefits beyond just controlling blood sugar.
SGLT2 inhibitors are known to reduce BP... reduce aortic stiffness, calories, body weight, and blood glucose and to increase osmotic diuresis... This mechanism is independent of insulin action or beta-cell function
Why this rating
Supported by multiple RCTs and meta-analyses cited in the review.
Source
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
Vani P. Sanon et al. · Therapeutics and Clinical Risk Management · 2017
DOI 10.2147/tcrm.s97619
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →